Chimeric Antigen Receptors: Driving Immunology Towards Synthetic Biology

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2016 Jul 4

PMID 27372731

Citations 53

Authors

Michel Sadelain

Affiliations

Soon will be listed here.

Abstract

The advent of second generation chimeric antigen receptors and the CD19 paradigm have ushered a new therapeutic modality in oncology. In contrast to earlier forms of adoptive cell therapy, which were based on the isolation and expansion of naturally occurring T cells, CAR therapy is based on the design and manufacture of engineered T cells with optimized properties. A new armamentarium, comprising not only CARs but also chimeric costimulatory receptors, chimeric cytokine receptors, inhibitory receptors and synthetic Notch receptors, expressed in naïve, central memory or stem cell-like memory T cells, is being developed for clinical use in a wide range of cancers. Immunological principles are thus finding a new purpose thanks to advances in genetic engineering, synthetic biology and cell manufacturing sciences.

Citing Articles

Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer.

Mussa A, Ismail N, Hamid M, Al-Hatamleh M, Bragoli A, Hajissa K J Exp Clin Cancer Res. 2024; 43(1):312.

PMID: 39609700 PMC: 11603874. DOI: 10.1186/s13046-024-03218-1.

CAR-engineered NK cells versus CAR T cells in treatment of glioblastoma; strength and flaws.

Sabahi M, Fathi Jouzdani A, Sadeghian Z, Dabbagh Ohadi M, Sultan H, Salehipour A J Neurooncol. 2024; 171(3):495-530.

PMID: 39538038 DOI: 10.1007/s11060-024-04876-z.

Ligand requirements for immunoreceptor triggering.

Barton M, Paterson R, Denham E, Goyette J, van der Merwe P Commun Biol. 2024; 7(1):1138.

PMID: 39271744 PMC: 11399299. DOI: 10.1038/s42003-024-06817-y.

UniCAR T-Cell Potency-A Matter of Affinity between Adaptor Molecules and Adaptor CAR T-Cells?.

Boutier H, Loureiro L, Hoffmann L, Arndt C, Bartsch T, Feldmann A Int J Mol Sci. 2024; 25(13).

PMID: 39000348 PMC: 11241561. DOI: 10.3390/ijms25137242.

CAR-NK cells in combination therapy against cancer: A potential paradigm.

Li J, Hu H, Lian K, Zhang D, Hu P, He Z Heliyon. 2024; 10(5):e27196.

PMID: 38486782 PMC: 10937699. DOI: 10.1016/j.heliyon.2024.e27196.

References

Sadelain M . CAR therapy: the CD19 paradigm. J Clin Invest. 2015; 125(9):3392-400. PMC: 4588281. DOI: 10.1172/JCI80010. View

Brocker T . Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood. 2000; 96(5):1999-2001. View

Morsut L, Roybal K, Xiong X, Gordley R, Coyle S, Thomson M . Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 2016; 164(4):780-91. PMC: 4752866. DOI: 10.1016/j.cell.2016.01.012. View

Ramos C, Savoldo B, Dotti G . CD19-CAR trials. Cancer J. 2014; 20(2):112-8. PMC: 3979594. DOI: 10.1097/PPO.0000000000000031. View

Miller J, Sadelain M . The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell. 2015; 27(4):439-49. DOI: 10.1016/j.ccell.2015.03.007. View

Pegram H, Lee J, Hayman E, Imperato G, Tedder T, Sadelain M . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 119(18):4133-41. PMC: 3359735. DOI: 10.1182/blood-2011-12-400044. View

Kochenderfer J . Genetic engineering of T cells in leukemia and lymphoma. Clin Adv Hematol Oncol. 2014; 12(3):190-2. View

Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J . Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010; 24(6):1160-70. PMC: 2888148. DOI: 10.1038/leu.2010.75. View

Oliveira G, Ruggiero E, Lupo Stanghellini M, Cieri N, DAgostino M, DAgostino M . Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci Transl Med. 2015; 7(317):317ra198. DOI: 10.1126/scitranslmed.aac8265. View

10.

Sadelain M, Brentjens R, Riviere I . The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009; 21(2):215-23. PMC: 5548385. DOI: 10.1016/j.coi.2009.02.009. View

11.

Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-9. PMC: 2267026. DOI: 10.1126/science.1129003. View

12.

Mitchison N . Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med. 1955; 102(2):157-77. PMC: 2136501. DOI: 10.1084/jem.102.2.157. View

13.

Kolb H, Schattenberg A, Goldman J, Hertenstein B, Jacobsen N, Arcese W . Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995; 86(5):2041-50. View

14.

Moon E, Ranganathan R, Eruslanov E, Kim S, Newick K, OBrien S . Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res. 2015; 22(2):436-47. PMC: 4715990. DOI: 10.1158/1078-0432.CCR-15-1070. View

15.

Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C . Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009; 32(2):169-80. PMC: 2683970. DOI: 10.1097/CJI.0b013e318194a6e8. View

16.

Bunnell B, Muul L, Donahue R, Blaese R, Morgan R . High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci U S A. 1995; 92(17):7739-43. PMC: 41221. DOI: 10.1073/pnas.92.17.7739. View

17.

Imai C, Mihara K, Andreansky M, Nicholson I, Pui C, Geiger T . Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004; 18(4):676-84. DOI: 10.1038/sj.leu.2403302. View

18.

Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D . Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013; 12(1):114-26. DOI: 10.1016/j.stem.2012.11.002. View

19.

Rosenberg S, TERRY W . Passive immunotherapy of cancer in animals and man. Adv Cancer Res. 1977; 25:323-88. DOI: 10.1016/s0065-230x(08)60637-5. View

20.

Carpenito C, Milone M, Hassan R, Simonet J, Lakhal M, Suhoski M . Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009; 106(9):3360-5. PMC: 2651342. DOI: 10.1073/pnas.0813101106. View